Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections

Medicine and Dentistry

• Age 16%
• All Cause Mortality 50%
• Antiviral Therapy 50%
• Combination Therapy 16%
• Diagnosis 33%
• Hematopoietic Stem Cell 66%
• Human Respiratory Syncytial Virus 100%
• Laboratory 16%
• Logistic Regression Analysis 16%
• Lower Respiratory Tract Infection 66%
• Lymphocytopenia 16%
• Male 16%
• Morbidity 33%
• Mortality 66%
• Neutropenia 16%
• Patient 33%
• Respiratory Syncytial Virus Infection 83%
• Retrospective Study 33%
• Ribavirin 83%
• Stem Cell Transplant 66%
• Upper Respiratory Tract Infection 50%
• Vulnerable Population 16%

Immunology and Microbiology

• Age 16%
• All Cause Mortality 50%
• Hematopoietic Stem Cell Transplantation 66%
• Human Respiratory Syncytial Virus 100%
• Lower Respiratory Tract 66%
• Lymphocytopenia 16%
• Morbidity 33%
• Mortality 66%
• Respiratory Syncytial Virus Infection 83%
• Ribavirin 83%
• Spectrum 16%
• Upper Respiratory Tract 50%
• Vulnerable Population 16%

Pharmacology, Toxicology and Pharmaceutical Science

• All Cause Mortality 50%
• Human Respiratory Syncytial Virus 100%
• Lower Respiratory Tract Infection 66%
• Lymphocytopenia 16%
• Morbidity 33%
• Mortality 66%
• Neutropenia 16%
• Respiratory Syncytial Virus Infection 83%
• Ribavirin 83%
• Upper Respiratory Tract Infection 50%